ASTRO 2022 | ARTFORCE: Rationale and study design of radiotherapy dose escalation and toxicity risks for HNC

Anneliz de Leeuw, MD, The Netherlands Cancer Institute, Amsterdam, Netherlands, explains the rationale and study design of the ARTFORCE trial (NCT01504815), which investigated the use of strategies to improve locoregional control and limit toxicity risks for locally advanced head and neck cancer. There is a need to increase locoregional control for locally advanced head and neck cancer patients, while limiting the increased risk of toxicity associated with dose escalation. The randomized Phase III ARTFOCE trial investigates strategies to implement this, including adaptive treatment to improve dose precision and dose redistribution. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.